Table 5.
Cervical cancer screening | |||||||||
---|---|---|---|---|---|---|---|---|---|
Cisgender Women n = 34,027 |
Cisgender Men n = 114 |
Transgender Women n = 13 |
Transgender Men n = 99 | Other n = 763 | Not Disclosed/ Unknown n = 4,959 |
X
2
(df) |
P-value | ||
|
|
||||||||
FQHC 1 (n = 2,822) | Screened n (%) | 1,461 (54%) | 1 (33%) | 1 (25%) | – | 1 (100%) | 32 (35%) | 0.0009+ | |
Not Screened n | 1262 | 2 | 3 | – | 0 | 59 | |||
FQHC 2 (n = 12,977) | Screened n (%) | 6,933 (64%) | – | 0 (0%) | 41 (59%) | 7 (47%) | 1,094 (55%) | 57.0991 (4) | < .0001++ |
Not Screened n | 3979 | – | 4 | 29 | 8 | 885 | |||
FQHC 3 (n = 13,488) | Screened n (%) | 8,112 (75%) | 22 (54%) | – | 5 (28%) | 4 (44%) | 1,786 (70%) | 50.1116 (4) | < .0001++ |
Not Screened n | 2771 | 19 | – | 13 | 5 | 751 | |||
FQHC 4 (n = 2,803) | Screened n (%) | 1,446 (53%) | 8 (62%) | – | 1 (33%) | 0 (0%) | 28 (35%) | 0.005+ | |
Not Screened n | 1260 | 5 | – | 2 | 1 | 52 | |||
FQHC 5 (n = 8,154) | Screened n (%) | 4,164 (61%) | 26 (46%) | 2 (40%) | 7 (88%) | 376 (51%) | 157 (58%) | < .0001+ | |
Not Screened n | 2639 | 31 | 3 | 1 | 361 | 115 | |||
Tobacco use: screening and cessation intervention | |||||||||
Cisgender Women n = 34,548 |
Cisgender Men n = 23,000 |
Transgender Women n = 173 |
Transgender Men n = 176 |
Other n = 677 |
Not Disclosed/Unknown n = 9,871 |
X
2
(df) |
P-value | ||
|
|
||||||||
FQHC 1 (n = 2,890) | Screened n (%) | 1,847 (97%) | 833 (90%) | 0 (0%) | 1 (100%) | – | 53 (88%) | < .0001+ | |
Not Screened n | 54 | 94 | 1 | 0 | – | 7 | |||
FQHC 2 (n = 27,254) | Screened n (%) | 13,050 (94%) | 8,022 (90%) | 138 (91%) | 105 (95%) | 32 (97%) | 3,611 (88%) | 161.0507 (5) | < .0001++ |
Not Screened n | 903 | 890 | 14 | 5 | 1 | 483 | |||
FQHC 3 (n = 25,084) | Screened n (%) | 11,509 (84%) | 4,965 (72%) | – | 38 (73%) | 16 (80%) | 4,257 (84%) | 498.8324 (4) | < .0001++ |
Not Screened n | 2184 | 1977 | – | 14 | 4 | 840 | |||
FQHC 4 (n = 4,360) | Screened n (%) | 2,753 (99%) | 1,462 (98%) | 6 (100%) | 7 (100%) | 1 (100%) | 83 (97%) | 0.0245+ | |
Not Screened n | 21 | 24 | 0 | 0 | 0 | 3 | |||
FQHC 5 (n = 8,137) | Screened n (%) | 1,955 (88%) | 4,329 (91%) | 12 (86%) | 5 (83%) | 552 (89%) | 473 (89%) | 26.6029 (5) | < .0001++ |
Not Screened n | 272 | 404 | 2 | 1 | 71 | 61 | |||
Screening for clinical depression and follow-up plan | |||||||||
Cisgender Women n = 31,662 |
Cisgender Men n = 25,027 |
Transgender Women n = 164 |
Transgender Men n = 155 |
Other n = 1,486 |
Not Disclosed/Unknown n = 13,077 |
X 2 (df) | P-value | ||
|
|
||||||||
FQHC 1 (n = 5,212) | Screened n (%) | 2,536 (81%) | 1,451 (79%) | 6 (75%) | 4 (100%) | 1 (50%) | 121 (57%) | < .0001+ | |
Not Screened n | 602 | 397 | 2 | 0 | 1 | 91 | |||
FQHC 2 (n = 23,161) | Screened n (%) | 8,887 (88%) | 7,009 (89%) | 125 (93%) | 78 (87%) | 33 (89%) | 3,037 (61%) | 2146.8855 (5) | < .0001++ |
Not Screened n | 1177 | 835 | 10 | 12 | 4 | 1954 | |||
FQHC 3 (n = 24,394) | Screened n (%) | 9,999 (87%) | 5,329 (86%) | 3 (100%) | 37 (73%) | 9 (64%) | 4,847 (73%) | < .0001+ | |
Not Screened n | 1529 | 863 | 0 | 14 | 5 | 1759 | |||
FQHC 4 (n = 4,333) | Screened n (%) | 2,273 (97%) | 1,570 (96%) | 3 (100%) | 1 (50%) | 1 (100%) | 318 (89%) | < .0001+ | |
Not Screened n | 67 | 59 | 0 | 1 | 0 | 40 | |||
FQHC 5 (14,471) | Screened n (%) | 4,048 (88%) | 6,680 (89%) | 14 (93%) | 8 (100%) | 1,260 (88%) | 816 (90%) | 4.4998 (5) | 0.4799++ |
Not Screened n | 544 | 834 | 1 | 0 | 172 | 94 |
Fisher’s Exact Test
Chi-square Test; FQHC = federally qualified health center; – = No patients reported